OrganaBio

Biotechnology ResearchFlorida, United States11-50 Employees

OrganaBio is a biotechnology company founded in 2018 and headquartered in Miami, Florida. It functions as a hub for tissue sourcing, clinical sample processing, and contract manufacturing services that support developers of cell and gene therapies globally. The firm emphasizes a data-driven approach across its strategically located facilities to deliver solutions where clients need them most. Its scope spans the development lifecycle, from proprietary tissue supply chains and cellular starting materials to development, testing, and other support activities intended to accelerate clinical translation. It operates a network of cell processing and cryopreservation laboratories across multiple U.S. locations.

Its customer base includes cell and gene therapy developers and clinical trial sponsors seeking GMP-grade starting materials and related manufacturing or support services. In 2024 it announced the launch of HematoPAC, a cGMP-compliant hematopoietic stem cell product ethically derived from cord blood. The company has expanded its footprint, opening a Hayward, California facility in 2025 and, in 2026, expanding to San Diego by acquiring assets from Excellos to create a coast-to-coast CDMO presence with autologous and allogeneic cell therapy capabilities. Its west coast labs in San Francisco and Irvine complement the Miami headquarters and other facilities, reflecting a nationwide network.

Sign up for free to view info

Email Format Employee directory